Fig. 3. Darapladib is able to promote ferroptosis in the absence of lipoprotein.

a, b Relative viability of Hs746T and SNU-484 cells treated with RSL3 and 2 μM darapladib cultured in medium containing FBS or LPDS for 6 h in the presence or absence of Fer-1. The data are presented as the means ± SDs (n = 3 or 4 independent experiments with, the significance of the results was assessed using a two-tailed Student’s t test). c Relative viability of cells in the indicated medium for 24 h. The data are presented as the means ± SDs (n = 3 independent experiments). d Relative viability of cells treated with RSL3 and 2 μM darapladib in the presence or absence of FBS. The data are presented as the means ± SDs (n = 3 or 4 independent experiments with, the significance of the results was assessed using a two-tailed Student’s t test). e Western blots showing the expression levels of well-known ferroptosis regulators upon 0.2 μM RSL3 and 2 μM darapladib treatment as indicated. Three blots were cut according to protein size and directed to western blotting, and reprobed to detect proteins of similar size. Each protein was normalised to α-tubulin on the same blot. Experiments were repeated three times and the data are also presented as the means ± SDs (n = 3 independent experiments). f Total iron level measured in the lysates of cells treated with 0.2 μM RSL3 and 2 μM darapladib. The data are presented as the means ± SDs (n = 4 independent experiments, with n.s. nonsignificant compared to the control with two-tailed Student’s t test). Exact p values provided as source data. Source data are provided as a source data file.